SENTHORIS turns any camera into a non-invasive screening layer for early neuro-metabolic, psychoactive, and cognitive risk — powered by Dynamic Pupil Light Response and AI/ML. No samples. No pain. No delay.
Validated through industry partners and global stages
Health assessed in 10 seconds — through the eyes.
No samples. No pain. No delay.
A software-first medical screening platform. Our IP lives in the algorithms and the proprietary clinical dataset — not in the sensor. The same AI/ML engine runs across mobile, kiosk, embedded automotive, and clinical-grade camera infrastructure.
SENTHORIS extracts a proprietary clinical signal from Dynamic Pupil Light Response (DPLR) — the microscopic, brain-mediated reaction of the pupil to a calibrated light stimulus. From that signal, AI/ML models infer early markers of metabolic dysregulation, psychoactive influence, and neuro-cognitive change. The screen takes under ten seconds.
The platform ships through three asset-light channels: embedded SDK for consumer and automotive OEMs, API for pharma and CRO data services, and SaaS for healthcare and government screening programmes. One AI engine, three go-to-markets, software-grade unit economics — designed for FDA SaMD certification as the regulatory anchor.
Three converging shifts — regulatory, market, and technical — have turned camera-based screening from a research curiosity into a defensible medical-software category.
With recreational cannabis legal across 24 US states, traditional drug-of-abuse testing has become legally and operationally fragile for employers, transportation, and oil & gas. Workplaces need an objective, real-time, non-invasive alternative.
Apple Watch ECG (510(k)), KardiaMobile, and the FDA's Digital Health Center of Excellence have already paved the route. Camera-derived physiological signals are now a recognised regulatory category for Software-as-a-Medical-Device.
Modern smartphone optics and AI/ML pipelines now resolve sub-millisecond pupil dynamics that previously required laboratory pupillometers. The measurement floor moved — and with it, the size of the addressable screening market.
Real-world engineering. Real customers. Real data. The validation chain compresses years of clinical insight into a credible path to FDA SaMD readiness.
Years of clinical pupillometry research transformed into AI/ML-ready data architecture and the first functional prototypes.
The signal pipeline confirmed under real-world operational conditions, outside laboratory settings.
Daily operational use at a major refinery checkpoint. Paying industrial customer. The deployment moved SENTHORIS from "validated technology" to "proven in production with real customers and real data".
Memorandum of Understanding signed at the Global Health Exhibition with Thermo Fisher's PPD™ Clinical Research business — establishing strategic intent to collaborate on the international clinical validation of SENTHORIS as Software-as-a-Medical-Device. A Tier-1 CRO has reviewed the project and committed to taking it forward.
Joint clinical programme across US and APAC sites in design with Thermo Fisher. Target: regulatory readiness for the FDA SaMD pathway, with parallel international certifications.
One AI/ML engine. Three asset-light go-to-market channels. Software-grade unit economics. The same proprietary dataset compounds across all of them.
Big Tech health platforms (Apple Health-class, Samsung Health-class), automotive driver-monitoring (DMS) for OEM and Tier-1 suppliers, and consumer wearables. Our software embeds into their devices and ships at their scale.
Pharma BD endpoints, CRO digital biomarker pipelines, occupational health TPAs. Direct integration into clinical, safety, and screening workflows.
Healthcare systems, government screening programmes, smart-city public-safety infrastructure. Subscription delivery — activated post-FDA SaMD certification.
Asset-light core team focused on AI/ML, mobile, and platform engineering. Clinical and regulatory delivery extends through Thermo Fisher rather than duplicated in-house — a deliberate choice that keeps unit economics software-grade.
A leading researcher and technology innovator with extensive experience in project leadership, manufacturing facility development, and product improvement. Dedicated to driving innovation through a scientific approach.
An experienced IT leader with 8+ years in .NET/C# development, system integration, and backend architecture. Skilled in building high-load services and digital platforms for industrial and medical sectors. Focused on turning complex technical challenges into reliable solutions that support business growth and digital transformation.
A seasoned international advisor guiding top-level executives across diverse enterprises. Strong strategic vision combined with a pragmatic approach to problem-solving, from initial concept development through successful implementation.
Shared with verified investors and strategic partners only. NDA available on request. We typically respond within 24 hours.
Request investor deck →— or —
Talk to founder on WhatsApp